Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025
Shots:
- Incyte has reported P-III (TRuE-PN: TRuE-PN1 & TRuE-PN2) clinical program data assessing Opzelura (BID) vs vehicle in ~180 PN pts (≥18yrs.) each for 12wks.
- TRuE-PN1 showed ≥4-point WI-NRS4 improvement at 12wks. (1EP; 44.6% vs 20.6%), with itch relief by Day 7 (22.4% vs 8.0%). It also met its 2EPs, incl. higher IGA-CPG-S-TS score (15.8% vs 3.9%) & treatment success (11.9% vs. 2.9%), with more pts achieving improved WI-NRS4 score by Wk. 4
- Additionally, TRuE-PN2 showed favorable trend across all 2EPs, particularly IGA-CPG-S-TS at Wk. 12 & WI-NRS4 (1EP) at Day 7, with 1EP also favoring therapy. However, statistical significance was not reached due to high PBO response; data to be presented at future meeting
Ref: Incyte | Image: Incyte
Related News:- Incyte Partners with Genesis to Develop and Commercialize Novel Small Molecules Using Genesis’ GEMS AI Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
